Deep Learning in Drug Discovery and Diagnostics (2017-2035) - By 2035, Deep Learning Solutions Can Result in Annual Savings of Over $35 Billion in the Diagnostics Segment Alone - Research and Markets

DUBLIN, Mar 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Deep Learning in Drug Discovery and Diagnostics, 2017 - 2035" report to their offering.

The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines the current landscape and future outlook of the growing market of deep learning solutions within the healthcare domain. Primarily driven by the big data revolution, deep learning algorithms have emerged as a novel solution to generate relevant insights from medical data.

Companies, such as Google, Amazon, Facebook, LinkedIn, IBM and Netflix, are already using deep learning algorithms to analyze users' activities and make customized suggestions and recommendations based on individual preferences. Today, in many ways, deep learning algorithms have enabled computers to see, read and write. In light of recent advances, the error rate associated with machines being able to analyze and interpret medical images has come down to 6%, which, some research groups claim, is even better than humans.

The likely benefits associated with the use of deep learning based solutions in the above mentioned areas is estimated to be worth multi billion dollars. There are well-known references where deep learning models have accelerated the drug discovery process and provided solutions to precision medicine. With potential applications in drug re-purposing and preclinical research, deep learning in drug discovery is likely to have great opportunity. In diagnostics, an increase in the speed of diagnosis is likely to have a profound impact in regions with large patient to physician ratios. The implementation of such solutions is anticipated to increase the efficiency of physicians providing a certain amount of relief to the overly-burdened global healthcare system.

Companies Mentioned

• CRG
• CureMetrix
• Facebook
• Fidelity Management & Research
• Finance Wales
• Finnish Funding Agency for Innovation
• First Round Capital
• Fitbit
• Flatiron Health
• Flipkart
• GE Ventures
• Google
• GSK
• Medtronic
• MedyMatch Technology
• Merck
• Merge Healthcare
• Metabolon
• Methinks Software
• Microsoft
• (300+ Others)
  

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. COMPANY PROFILES

6. CASE STUDY: IBM WATSON VERSUS GOOGLE DEEPMIND

7. CAPITAL INVESTMENTS AND FUNDING

8. OPPORTUNITY ANALYSIS

9. COMPANY VALUATION ANALYSIS

10. DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS

11. CONCLUSION

For more information about this report visit http://www.researchandmarkets.com/research/2svrc3/deep_learning_in

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets